INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845P958. A total of 5 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $986 | -16.9% | 53,200 | -50.5% | 0.00% | 0.0% |
| Q2 2023 | $1,187 | -23.5% | 107,400 | -7.0% | 0.00% | 0.0% |
| Q1 2023 | $1,551 | +19.3% | 115,500 | +9.9% | 0.00% | 0.0% |
| Q4 2022 | $1,300 | -99.9% | 105,100 | -8.2% | 0.00% | -50.0% |
| Q3 2022 | $1,597,000 | +603.5% | 114,500 | +593.9% | 0.00% | – |
| Q2 2022 | $227,000 | -90.2% | 16,500 | -88.4% | 0.00% | -100.0% |
| Q1 2022 | $2,315,000 | +120.1% | 142,300 | +120.3% | 0.00% | +100.0% |
| Q4 2021 | $1,052,000 | +87.2% | 64,600 | +134.9% | 0.00% | 0.0% |
| Q3 2021 | $562,000 | +2.4% | 27,500 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $549,000 | +25.9% | 27,500 | +14450.3% | 0.00% | 0.0% |
| Q1 2021 | $436,000 | -36.4% | 189 | -32.0% | 0.00% | 0.0% |
| Q4 2020 | $686,000 | +12.6% | 278 | +89.1% | 0.00% | 0.0% |
| Q3 2020 | $609,000 | -71.5% | 147 | -67.0% | 0.00% | -66.7% |
| Q2 2020 | $2,136,000 | -43.9% | 446 | -26.3% | 0.00% | -57.1% |
| Q1 2020 | $3,809,000 | -62.0% | 605 | -25.1% | 0.01% | -68.2% |
| Q4 2019 | $10,012,000 | +325.1% | 808 | +127.6% | 0.02% | +214.3% |
| Q3 2019 | $2,355,000 | +7.2% | 355 | +28.6% | 0.01% | +16.7% |
| Q2 2019 | $2,196,000 | -75.9% | 276 | -66.1% | 0.01% | -76.0% |
| Q1 2019 | $9,094,000 | +58.9% | 813 | +43.1% | 0.02% | +47.1% |
| Q4 2018 | $5,724,000 | +36.1% | 568 | +70.6% | 0.02% | +21.4% |
| Q3 2018 | $4,207,000 | +311.2% | 333 | +173.0% | 0.01% | +250.0% |
| Q2 2018 | $1,023,000 | +1987.8% | 122 | +90.6% | 0.00% | +100.0% |
| Q1 2018 | $49,000 | -95.4% | 64 | -77.0% | 0.00% | -95.7% |
| Q4 2017 | $1,070,000 | -26.1% | 278 | -40.0% | 0.05% | -22.0% |
| Q3 2017 | $1,447,000 | +642.1% | 463 | +65.4% | 0.06% | +637.5% |
| Q2 2017 | $195,000 | +2.1% | 280 | -2.4% | 0.01% | 0.0% |
| Q1 2017 | $191,000 | -74.4% | 287 | -48.6% | 0.01% | -82.2% |
| Q4 2016 | $745,000 | +187.6% | 558 | +121.4% | 0.04% | +150.0% |
| Q3 2016 | $259,000 | -41.4% | 252 | +5.0% | 0.02% | -40.0% |
| Q2 2016 | $442,000 | +92.2% | 240 | +15.4% | 0.03% | +66.7% |
| Q1 2016 | $230,000 | -27.7% | 208 | +147.6% | 0.02% | -28.0% |
| Q4 2015 | $318,000 | -61.3% | 84 | +21.7% | 0.02% | -58.3% |
| Q3 2015 | $821,000 | +15.3% | 69 | -41.0% | 0.06% | 0.0% |
| Q2 2015 | $712,000 | +143.8% | 117 | -22.5% | 0.06% | +76.5% |
| Q1 2015 | $292,000 | -42.1% | 151 | +60.6% | 0.03% | -44.3% |
| Q4 2014 | $504,000 | – | 94 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Caligan Partners LP | 1,200,000 | $22,248,000 | 10.22% |
| GROUP ONE TRADING, L.P. | 24,800 | $459,792 | 0.00% |
| SIMPLEX TRADING, LLC | 53,200 | $986 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| JANE STREET GROUP, LLC | 68,500 | $1,269,990 | 0.00% |